GLF
FOLD

Groupe la Francaise’s Amicus Therapeutics FOLD Stock Holding History

Groupe la Francaise’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6M Buy
939,655
+705,453
+301% +$10.1M 0.19% 89
2025
Q4 		$3.34M Buy
+234,202
New +$2.3M 0.05% 215

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Groupe la Francaise's FOLD Position: Q1 2026 in Review

Groupe la Francaise increased its Amicus Therapeutics (FOLD) stake by 301% in Q1 2026, buying an estimated $10.1M and bringing the position to 939,655 shares worth $13.6M. The position accounts for 0.19% of the portfolio, ranked #89.

Groupe la Francaise first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Groupe la Francaise held 939,655 shares of Amicus Therapeutics worth $13.6M as of Q1 2026.
  • Groupe la Francaise bought 705,453 Amicus Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Amicus Therapeutics made up 0.19% of Groupe la Francaise's portfolio in Q1 2026, its #89 holding.
  • Groupe la Francaise first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Groupe la Francaise's 13F filing for Q1 2026, filed 21 May 2026.